Interstitial Lung Disease Market Size, Insights, Outlook, Overview And Market Research Report 2024-2033

"The new report published by The Business Research Company, titled Interstitial Lung Disease Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the interstitial lung disease market size has grown strongly in recent years. It will grow from $1.83 billion in 2023 to $1.97 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The interstitial lung disease market size is expected to see strong growth in the next few years. It will grow to $2.62 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13019&type=smp

Role Of Allergic Conditions In Driving Growth Of The Interstitial Lung Disease Market
The growing prevalence of allergic conditions is expected to propel the growth of the interstitial lung disease market going forward. An allergic condition is when the immune system overreacts to an allergen, often known as a harmless substance. Allergic reactions might result in interstitial lung disease (ILD), specifically hypersensitivity pneumonitis, which causes an allergic reaction in the body causes hypersensitivity pneumonitis. For instance, in January 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency for public health, over one-third of American adults and more than one-fourth of American children had a seasonal allergy, eczema, or food allergy in 2021. Further, anaphylaxis (a severe allergic reaction to food) is estimated to cause 90,000 emergency room visits in the United States each year. Therefore, the growing prevalence of allergic conditions is driving the growth of the interstitial lung disease market.

Innovative Drug Development Initiatives To Improve Interstitial Lung Disease Treatment
Major Companies operating in the interstitial lung disease market are focusing on developing innovative drugs to treat their customers and sustain their position in the market. The development of new drugs can improve treatment outcomes for patients with lung-related diseases. For instance, in April 2021, United Therapeutics, a US-based biotechnology company, launched Tyvaso, a medication for treating patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. Tyvaso is a treatment for patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). It is a sterile version of the prostacyclin-mimicking drug treprostinil that is meant to be inhaled orally utilizing the Tyvaso inhalation system.

The interstitial lung disease market covered in this report is segmented -

1) By Drug Type: Oral Corticosteroids; Immune Suppressing; Anti-Fibrotic Medication; Other Drugs
2) By Disease Type: Interstitial Pneumonia; Idiopathic Pulmonary Fibrosis; Nonspecific Interstitial Pneumonitis; Hypersensitivity Pneumonitis; Cryptogenic Organizing Pneumonia (COP); Sarcoidosis; Acute Interstitial Pneumonitis
3) By Application: Adults; Children
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13019&type=discount

Major players in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Siemens Healthineers, Koninklijke Philips N.V., Teva Pharmaceuticals USA Inc., AstraZeneca PLC, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Fujirebio Diagnostics Inc., Insmed Inc., VIDA Diagnostics Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health PLC, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc.

Contents of the report:
1. Executive Summary
2. Interstitial Lung Disease Market Report Structure
3. Interstitial Lung Disease Market Trends And Strategies
4. Interstitial Lung Disease Market - Macro Economic Scenario
5. Interstitial Lung Disease Market Size And Growth
…..
27. Interstitial Lung Disease Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.